Washington, D.C., February 13, 2018—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, today followed up on the recent coalition letter emphasizing the patient and provider community’s opposition to the Right to Try Act (H.R.878 and S.204) with a one-pager which distills why the Right to Try Act simply will not increase access to promising investigational therapies for patients, and will instead remove critical patient protections.
We once again urge you to oppose this legislation and join the patient community in requesting legislation that will actually help our community, not harm it.
